BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 34389744)

  • 21. Differential expression of Snail1 transcription factor and Snail1-related genes in alveolar and embryonal rhabdomyosarcoma subtypes.
    Püsküllüoglu M; Lukasiewicz E; Miekus K; Jarocha D; Majka M
    Folia Histochem Cytobiol; 2010 Dec; 48(4):671-7. PubMed ID: 21478114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype.
    Kohashi K; Oda Y; Yamamoto H; Tamiya S; Takahira T; Takahashi Y; Tajiri T; Taguchi T; Suita S; Tsuneyoshi M
    J Cancer Res Clin Oncol; 2008 Oct; 134(10):1097-103. PubMed ID: 18386058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Berberine and palmatine inhibit the growth of human rhabdomyosarcoma cells.
    Shinji S; Nakamura S; Nihashi Y; Umezawa K; Takaya T
    Biosci Biotechnol Biochem; 2020 Jan; 84(1):63-75. PubMed ID: 31462179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
    Megiorni F; Camero S; Ceccarelli S; McDowell HP; Mannarino O; Marampon F; Pizer B; Shukla R; Pizzuti A; Marchese C; Clerico A; Dominici C
    Oncotarget; 2016 Nov; 7(48):79342-79356. PubMed ID: 27764816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
    Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
    Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Close correlation between CXCR4 and VEGF expression and frequent CXCR7 expression in rhabdomyosarcoma.
    Miyoshi K; Kohashi K; Fushimi F; Yamamoto H; Kishimoto J; Taguchi T; Iwamoto Y; Oda Y
    Hum Pathol; 2014 Sep; 45(9):1900-9. PubMed ID: 25086956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
    Odeniyide P; Yohe ME; Pollard K; Vaseva AV; Calizo A; Zhang L; Rodriguez FJ; Gross JM; Allen AN; Wan X; Somwar R; Schreck KC; Kessler L; Wang J; Pratilas CA
    Oncogene; 2022 May; 41(21):2973-2983. PubMed ID: 35459782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.
    Crose LE; Galindo KA; Kephart JG; Chen C; Fitamant J; Bardeesy N; Bentley RC; Galindo RL; Chi JT; Linardic CM
    J Clin Invest; 2014 Jan; 124(1):285-96. PubMed ID: 24334454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
    van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
    Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma.
    Slemmons KK; Crose LE; Rudzinski E; Bentley RC; Linardic CM
    PLoS One; 2015; 10(10):e0140781. PubMed ID: 26496700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic MIR143-3p Suppresses Cell Growth in Rhabdomyosarcoma Cells by Interrupting RAS Pathways Including PAX3-FOXO1.
    Sugito N; Heishima K; Ito Y; Akao Y
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33182548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
    Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
    Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis.
    Allen-Rhoades W; Lupo PJ; Scheurer ME; Chi YY; Kuttesch JF; Venkatramani R; Meyer WH; Mascarenhas L
    Cancer Med; 2023 May; 12(9):10222-10229. PubMed ID: 37016270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequent HRAS Mutations in Malignant Ectomesenchymoma: Overlapping Genetic Abnormalities With Embryonal Rhabdomyosarcoma.
    Huang SC; Alaggio R; Sung YS; Chen CL; Zhang L; Kao YC; Agaram NP; Wexler LH; Antonescu CR
    Am J Surg Pathol; 2016 Jul; 40(7):876-85. PubMed ID: 26872011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
    Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM
    Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Ahn EH; Mercado GE; Laé M; Ladanyi M
    Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular biology of rhabdomyosarcoma.
    Gallego Melcón S; Sánchez de Toledo Codina J
    Clin Transl Oncol; 2007 Jul; 9(7):415-9. PubMed ID: 17652054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status.
    Corao DA; Biegel JA; Coffin CM; Barr FG; Wainwright LM; Ernst LM; Choi JK; Zhang PJ; Pawel BR
    Pediatr Dev Pathol; 2009; 12(4):275-83. PubMed ID: 18788887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
    Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
    Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.